| 1 |
NCT02413073 |
Completed |
Whole Body Vibration in Kidney Disease |
|
- Procedure: Whole Body Vibration
|
Interventional |
Phase 4 |
- Universidade Federal de Pernambuco
|
Other |
- Allocation: Randomized
- Intervention Model: Factorial Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- muscle strength, as measured by isokinetic dynamometer (Kgf)
- postural equilibrium, as measured by biodex balance (score)
- functional capacity, as measured by 6MWT
- (and 2 more...)
|
16 |
All |
40 Years to 74 Years (Adult, Senior) |
NCT02413073 |
35872014.8.00005208 |
|
April 2015 |
August 2016 |
October 2016 |
April 9, 2015 |
November 15, 2016 |
|
|
| 2 |
NCT02558595 |
Active, not recruiting |
Pilot Study of Niacinamide in Polycystic Kidney Disease (NIAC-PKD2) |
- Polycystic Kidney Disease
|
- Dietary Supplement: Niacinamide
- Other: Placebo
|
Interventional |
Phase 2 |
- University of Kansas Medical Center
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Basic Science
|
- Change in acetylated/total p53 ratio measured by ELISA in peripheral blood mononuclear cells (PBMC)
- Change in height-adjusted total kidney volume
- Change in score on pain questionnaire
- (and 2 more...)
|
36 |
All |
18 Years to 60 Years (Adult) |
NCT02558595 |
STUDY00002827
R21DK104086 |
|
September 2015 |
December 2017 |
December 2018 |
September 24, 2015 |
April 5, 2018 |
|
- University of Kansas Medical Center
Kansas City, Kansas, United States
|
| 3 |
NCT02936791 |
Recruiting |
Early-Stage Polycystic Kidney Disease Biomarkers Repository Study |
- Polycystic Kidney Disease
|
|
Observational |
|
- University of Kansas Medical Center
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Collect blood and urine samples from affected and unaffected cohorts for basic and translational research
|
250 |
All |
up to 35 Years (Child, Adult) |
NCT02936791 |
STUDY00003383
P30DK106912 |
|
April 2016 |
June 2020 |
June 2020 |
October 18, 2016 |
February 7, 2018 |
|
- University of Chicago
Chicago, Illinois, United States - University of Kansas Medical Center
Kansas City, Kansas, United States - Children's Mercy Hospital
Kansas City, Missouri, United States
|
| 4 |
NCT03358966 |
Completed |
Energy Expenditure in Chronic Kidney Disease |
- Kidney Diseases
- Chronic Kidney Diseases
|
- Other: Doubly-labelled water technique
- Other: Resting Energy Expenditure
|
Observational |
|
- East and North Hertfordshire NHS Trust
- University of Hertfordshire
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Energy expenditure using doubly labelled water
- Whole body bioimpedance
- Resting Energy Expenditure using indirect calorimetry
- Stanford 7 day recall questionnaire physical activity level
|
80 |
All |
18 Years and older (Adult, Senior) |
NCT03358966 |
08/H/0311/103 (REC No.)
RP27/2010 |
|
September 1, 2008 |
May 30, 2014 |
May 30, 2015 |
December 2, 2017 |
December 4, 2017 |
|
|
| 5 |
NCT02937350 |
Recruiting |
Clearance of 25-hydroxyvitamin D in Chronic Kidney Disease |
|
- Drug: D6-25-hydroxyvitamin D3
|
Interventional |
Phase 1 |
- University of Washington
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Metabolic clearance of D6-25(OH)D3
- AUC of D6-25(OH)D3
- Terminal half-life of D6-25(OH)D3
- Volume of distribution of D6-25(OH)D3
|
120 |
All |
18 Years and older (Adult, Senior) |
NCT02937350 |
42430
R01DK099199 |
CLEAR |
March 1, 2017 |
December 2020 |
December 2020 |
October 18, 2016 |
March 26, 2018 |
|
- University of Washington
Seattle, Washington, United States
|
| 6 |
NCT02177786 |
Completed |
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease |
|
- Drug: Selonsertib
- Drug: Placebo to match selonsertib
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in estimated glomerular filtration rate (eGFR) from baseline at Week 48
- Proportion of participants achieving at least a 30% reduction from baseline in albuminuria at Week 48
|
334 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT02177786 |
GS-US-223-1015 |
|
June 2014 |
July 2016 |
August 2016 |
June 30, 2014 |
January 13, 2017 |
|
- The University of Alabama at Birmingham (UAB)
Birmingham, Alabama, United States - Chase Medcare
Huntsville, Alabama, United States - Choice Medicine
Toney, Alabama, United States - (and 102 more...)
|
| 7 |
NCT03009864 |
Not yet recruiting |
The Multi-Center Clinical Study of Tang Shen Prescription on Type 2 Diabetic Kidney Disease in Early Stage |
|
- Drug: Tangshen Prescription
- Drug: Placebos
|
Interventional |
Early Phase 1 |
- Guang'anmen Hospital of China Academy of Chinese Medical Sciences
- Anhui Provincial Hospital of Traditional Chinese Medicine
- Zhengzhou City Hospital of Traditional Chinese Medicine
- (and 10 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- changes of albumin-to-creatinine ration
- number of participants of diabetic kidney disease in macroalbuminuria stage
- number of participants whose microalbuminuria excretion rate < 20ug/min
- (and 2 more...)
|
632 |
All |
30 Years to 70 Years (Adult, Senior) |
NCT03009864 |
201507001-11Tangshen |
|
January 2017 |
September 2019 |
May 2020 |
January 4, 2017 |
January 4, 2017 |
|
- Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Beijing, Beijing, China
|
| 8 |
NCT01693744 |
Completed |
Pseudoexfoliation and Chronic Kidney Disease |
|
|
Observational |
|
|
Other |
- Observational Model: Case Control
- Time Perspective: Prospective
|
- Prevalance of pseudoexfoliation in patients with chronic kidney disease
|
358 |
All |
40 Years to 80 Years (Adult, Senior) |
NCT01693744 |
LNiyaz |
|
October 2011 |
|
April 2012 |
September 26, 2012 |
September 26, 2012 |
|
- Corum State Hospital
Corum, Turkey
|
| 9 |
NCT02299310 |
Unknown † |
Effect of Valsartan vs Perindopril on HOMA-IR Index in Patients With Chronic Kidney Disease |
|
- Drug: Valsartan
- Drug: Perindopril
|
Interventional |
Phase 4 |
- Chinese PLA General Hospital
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Homeostasis model of assessment for insulin resistence index (HOMA-IR index)
- Glomerular filtration rate(eGFR) and Creatinine clearance rate(CCR)
- Body mass index(BMI)
- (and 3 more...)
|
60 |
All |
Child, Adult, Senior |
NCT02299310 |
S2014-088 |
|
November 2014 |
November 2015 |
December 2015 |
November 24, 2014 |
December 2, 2014 |
|
- Chinese PLA General Hospital
Beijing, Beijing, China
|
| 10 |
NCT03227055 |
Recruiting |
Cardiovascular Comorbidity in Children With Chronic Kidney Disease |
- Childhood Chronic Kidney Disease
|
|
Observational |
|
- Chang Gung Memorial Hospital
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
|
155 |
All |
3 Years to 18 Years (Child, Adult) |
NCT03227055 |
201601181A3 |
|
December 30, 2016 |
December 31, 2019 |
December 31, 2019 |
July 24, 2017 |
July 24, 2017 |
|
- Kaohsiung Chang Gung Memorial Hospital
Kaohsiung, Taiwan
|
| 11 |
NCT03400228 |
Completed |
Effect of Probiotic Consumption on Chronic Kidney Disease |
|
- Dietary Supplement: Probiotic
- Dietary Supplement: Maltodextrin
|
Interventional |
Not Applicable |
- Centro Universitário Univates
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Other
|
- Decrease in serum creatinine level
- Reduced levels of serum lipids
|
30 |
All |
18 Years and older (Adult, Senior) |
NCT03400228 |
072015 |
|
July 1, 2015 |
July 1, 2015 |
December 31, 2017 |
January 17, 2018 |
January 17, 2018 |
|
- Thaís Rodrigues Moreira
Porto Alegre, Rio Grande Do Sul, Brazil
|
| 12 |
NCT02336776 |
Unknown † |
Functional Electrical Stimulation in Chronic Kidney Disease |
|
- Other: Functional electrical stimulation
|
Interventional |
Not Applicable |
- Federal University of Health Science of Porto Alegre
- Irmandade Santa Casa de Misericórdia de Porto Alegre
- Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul, Brazil
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Functional capacity
- Muscle architecture
- Muscle strength of the lower limbs
- (and 5 more...)
|
21 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT02336776 |
FESCKD |
|
May 2014 |
August 2014 |
March 2015 |
January 13, 2015 |
January 13, 2015 |
|
|
| 13 |
NCT03423810 |
Not yet recruiting |
Assessing a Dose‐Response Relationship of Hydralazine and Its Effects on DNA Methyltransferase 1 in Polycystic Kidney Disease Patients |
- Polycystic Kidney Diseases
|
|
Interventional |
Early Phase 1 |
- University of Kansas Medical Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Change in polycystin-1 (PC1)
- Change in mucin-like protocadherin (MUPCDH)
- Circulating methylated RASAL1 levels
|
10 |
All |
18 Years to 65 Years (Adult) |
NCT03423810 |
STUDY00141337
UL1TR002366 |
|
April 15, 2018 |
February 15, 2019 |
May 15, 2019 |
February 6, 2018 |
April 5, 2018 |
|
- University of Kansas Medical Center
Kansas City, Kansas, United States
|
| 14 |
NCT02195323 |
Completed |
Autologous Bone Marrow Derived Mesenchymal Stromal Cells (BM-MSCs) in Patients With Chronic Kidney Disease (CKD) |
|
- Biological: Intravenous injection
|
Interventional |
Phase 1 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- mass formation
- Creatinin
- GFR
|
7 |
All |
25 Years to 60 Years (Adult) |
NCT02195323 |
Royan-Kidney-004 |
|
April 2014 |
December 2015 |
January 2016 |
July 21, 2014 |
January 5, 2016 |
|
- Royan Institute
Tehran, Iran, Islamic Republic of
|
| 15 |
NCT02585622 |
Recruiting |
NEPHSTROM for Diabetic Kidney Disease |
|
- Biological: Mesenchymal Stromal Cells
- Other: Placebo
|
Interventional |
Phase 1
Phase 2 |
- Mario Negri Institute for Pharmacological Research
- Leiden University Medical Center
- ASST Papa Giovanni XXIII, Bergamo, Italy
- (and 5 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Other
|
- Number and severity of all pre-specified infusion-associated events and the overall number and frequency of adverse events.
- Glomerular filtration rate (GFR)
- Urinary Albumin/Creatinine Ratio (ACR)
- (and 15 more...)
|
48 |
All |
40 Years to 85 Years (Adult, Senior) |
NCT02585622 |
NEPHSTROM
2016-000661-23 |
NEPHSTROM |
December 11, 2017 |
June 2020 |
December 2020 |
October 23, 2015 |
March 21, 2018 |
|
- National University of ireland - Galway University Hospital -Regenerative Medicine Institute
Galway, Ireland - ASST - Papa Giovanni XXIII - U.O. Nefrologia e Dialisi/ Mario Negri Institute for Pharmacological Research - Clinical Research Center for Rare Diseases Aldo e Cele Daccò
Bergamo, BG, Italy - Belfast Health and Social Care Trust - Belfast City Hospital
Belfast, United Kingdom - University Hospital Birmingham NHS Foundation Trust - Queen Elizabeth Medical Centre
Birmingham, United Kingdom
|
| 16 |
NCT02155127 |
Completed |
Effects of a Walking Intervention in Older Patients With Chronic Kidney Disease: Feasibility Study |
|
|
Interventional |
Not Applicable |
- University of Utah
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
80 |
All |
60 Years and older (Adult, Senior) |
NCT02155127 |
IRB_00064407 |
|
October 2014 |
October 2016 |
October 2016 |
June 4, 2014 |
November 18, 2016 |
|
- University of Utah
Salt Lake City, Utah, United States
|
| 17 |
NCT03393663 |
Completed |
Chronic Kidney Disease: Determinants of Progression and Cardiovascular Risk |
|
- Other: CKD-related outcomes
|
Observational |
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Overall Mortality
- Renal replacement therapy
|
454 |
All |
30 Years and older (Adult, Senior) |
NCT03393663 |
2011/17341-0 |
PROGREDIR |
March 1, 2012 |
December 15, 2013 |
December 15, 2013 |
January 8, 2018 |
January 8, 2018 |
|
|
| 18 |
NCT03305211 |
Not yet recruiting |
Biological Collection in Nephrology for the Study of the Links Between Kidney Disease, Immunity System and Cardiovascular Complications |
|
|
Interventional |
Not Applicable |
- Assistance Publique Hopitaux De Marseille
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Blood and urinary biomarkers in renal disease
|
600 |
All |
18 Years and older (Adult, Senior) |
NCT03305211 |
2017-49 |
NéphroMIC² |
December 15, 2017 |
December 15, 2022 |
April 20, 2023 |
October 9, 2017 |
October 9, 2017 |
|
- Assistance Publique des Hôpitaux de Marseille Hôpital de la Conception
Marseille, France
|
| 19 |
NCT01838330 |
Completed |
Effects of High Dietary Fiber Supplementation in Diabetic Chronic Kidney Disease |
|
- Dietary Supplement: psyllium
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- p-cresyl sulfate serum concentration
- Indoxyl sulfate serum concentration
- Interleukin-6 (IL-6) serum concentration
|
44 |
All |
18 Years to 90 Years (Adult, Senior) |
NCT01838330 |
IRB_00052609 |
|
June 2012 |
January 2016 |
January 2016 |
April 24, 2013 |
August 11, 2016 |
|
- University of Utah nephrology clinics, the internal medicine and endocrinology clinics
Salt Lake City, Utah, United States
|
| 20 |
NCT02251275 |
Active, not recruiting |
Open-label Trial to Evaluate the Long Term Safety of Titrated Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease |
- Autosomal Dominant Polycystic Kidney Disease
|
- Drug: Tolvaptan (OPC-41061)
|
Interventional |
Phase 3 |
- Otsuka Pharmaceutical Development & Commercialization, Inc.
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
2500 |
All |
18 Years and older (Adult, Senior) |
NCT02251275 |
156-13-211 |
|
September 2014 |
May 2018 |
|
September 29, 2014 |
June 21, 2017 |
|
- Birmingham, Alabama, United States
- Huntsville, Alabama, United States
- Mobile, Alabama, United States
- (and 204 more...)
|
| 21 |
NCT01452360 |
Unknown † |
A Research Proposal to Set up an Integrated National Data Bank and Monitoring System and to Establish the Indicators and Risk Factors for Chronic Kidney Disease |
|
|
Observational |
|
- Taipei Medical University WanFang Hospital
|
Other |
|
|
700 |
All |
20 Years and older (Adult, Senior) |
NCT01452360 |
100009 |
|
May 2011 |
|
May 2014 |
October 14, 2011 |
October 14, 2011 |
|
- Taipei Medical University - Shuang-Ho Hospital
Taipei, Taiwan
|
| 22 |
NCT02176278 |
Recruiting |
Using a Diabetic Kidney Disease (DKD) Registry to Treat to Multiple Targets (TMT) |
|
- Other: Telephone Reminder
- Other: Doctor-Nurse Follow Up
- Other: Personalized Risk Report for Patient Empowerment
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Attainment of at least 3 treatment targets
- Incidence of all-diabetes related endpoints
|
3000 |
All |
Child, Adult, Senior |
NCT02176278 |
CRE-2013.609-T |
DKD-TMT |
May 2014 |
January 2018 |
January 2018 |
June 27, 2014 |
August 15, 2016 |
|
- The Forth Affiliated Hospital of China Medical University
Shengyang City, China - Chinese University of Hong Kong, Prince of Wales Hospital
Hong Kong, Hong Kong - Department of Medicine, Alice Ho Miu Ling Nethersole Hospital
Hong Kong, Hong Kong - (and 9 more...)
|
| 23 |
NCT02992548 |
Active, not recruiting |
Effect of Pravastatin on Erythrocyte Membrane Fatty Acid Contents in Patients With Chronic Kidney Disease |
|
|
Interventional |
Phase 4 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- mean change of erythrocyte membrane fatty acid including oleic acid
- mean change of total cholesterol
- mean change of triglyceride
- (and 3 more...)
|
62 |
All |
20 Years to 80 Years (Adult, Senior) |
NCT02992548 |
prava_2016 |
|
September 2015 |
August 2018 |
August 2018 |
December 14, 2016 |
March 27, 2018 |
|
- Dong-A University
Busan, Korea, Republic of - Inje University, Pusan Paik Hospital
Busan, Korea, Republic of
|
| 24 |
NCT03412006 |
Recruiting |
A Double-blind Study to Investigate Efficacy, Safety and Tolerability of BAY1142524 in Patients With Type II Diabetes and a Clinical Diagnosis of Diabetic Kidney Disease |
|
- Drug: Fulacimstat (BAY1142524)
- Drug: Placebo
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in urinary albumin to creatinine ratio (UACR)
- Number of patients with treatment-emergent adverse event
- Number of patients with serious adverse events
|
107 |
All |
18 Years to 79 Years (Adult, Senior) |
NCT03412006 |
18933
2017-000656-26 |
CADA DIA |
February 2, 2018 |
July 25, 2019 |
August 15, 2019 |
January 26, 2018 |
April 18, 2018 |
|
- Med Centre Diamedical 2013
Dimitrovgrad, Bulgaria - MCOMH Preventsia-2000
Stara Zagora, Bulgaria - Med. Center Equita
Varna, Bulgaria - (and 20 more...)
|
| 25 |
NCT02863185 |
Recruiting |
Effect of Pitavastatin on Erythrocyte Membrane Fatty Acid Contents in Patients With Chronic Kidney Disease |
|
- Drug: Pitavastatin
- Drug: Atorvastatin
|
Interventional |
Phase 4 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- mean difference and change of erythrocyte membrane fatty acid including oleic acid
- mean difference and change of total cholesterol, triglyceride, LDL-cholesterol, HDL-cholesterol
- mean difference and change of adiponectin
- (and 2 more...)
|
72 |
All |
20 Years to 80 Years (Adult, Senior) |
NCT02863185 |
Pita_2016 |
|
May 2016 |
December 2019 |
December 2019 |
August 11, 2016 |
March 27, 2018 |
|
- Won Suk An
Busan, Korea, Republic of - Dong-A University
Busan, Korea, Republic of
|
| 26 |
NCT02805348 |
Active, not recruiting |
Post-marketing Surveillance of Bixalomer in Patients With Pre-dialysis Chronic Kidney Disease |
|
|
Observational |
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Change from baseline in the serum concentrations of phosphate
- Change from baseline in the corrected serum concentrations of calcium
- Change from baseline in the serum concentrations of intact parathyroid hormone
- Safety assessed by incidence of adverse events
|
144 |
All |
Child, Adult, Senior |
NCT02805348 |
1585-MA-3052 |
|
June 1, 2016 |
December 2018 |
December 2018 |
June 20, 2016 |
February 15, 2018 |
|
- Site JP00006
Aichi, Japan - Site JP00010
Ehime, Japan - Site JP00012
Fukuoka, Japan - (and 11 more...)
|
| 27 |
NCT00800878 |
Unknown † |
Chronic Kidney Disease in Pakistani Population |
|
|
Observational |
|
- Aga Khan University
- National Institutes of Health (NIH)
|
Other / NIH |
- Time Perspective: Cross-Sectional
|
- GFR will be measured as the mean of at least two urinary clearance periods of Inulin
|
650 |
All |
40 Years and older (Adult, Senior) |
NCT00800878 |
R03TW007588 |
CKD |
February 2008 |
December 2009 |
April 2010 |
December 2, 2008 |
December 9, 2008 |
|
- Aga Khan University
Karachi, Sindh, Pakistan
|
| 28 |
NCT02140814 |
Completed |
Uncontrolled, Open Label, Pilot and Feasibility Study of Niacinamide in Polycystic Kidney Disease |
- Polycystic Kidney Disease
|
- Dietary Supplement: Niacinamide
|
Interventional |
Phase 2 |
- Alan Yu, MB, BChir
- University of Kansas Medical Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Sirtuin deacetylase activity
- Estimated Glomerular Filtration Rate (eGFR)
- Height-adjusted total kidney volumes (htTKV)
- (and 2 more...)
|
10 |
All |
18 Years to 50 Years (Adult) |
NCT02140814 |
STUDY00000874 |
NIAC-PKD1 |
May 2014 |
February 2016 |
|
May 16, 2014 |
December 1, 2016 |
|
- University of Kansas Medical Center
Kansas City, Kansas, United States
|
| 29 |
NCT01988038 |
Withdrawn |
Repository Study of Autosomal Dominant Polycystic Kidney Disease |
- Autosomal Dominant Polycystic Kidney Disease
|
|
Observational |
|
- The Rogosin Institute
- Weill Medical College of Cornell University
- New York Presbyterian Hospital
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Natural history of Autosomal Dominant Polycystic Kidney Disease (ADPKD) progression
|
0 |
All |
18 Years and older (Adult, Senior) |
NCT01988038 |
1305013979 |
Repository |
November 2013 |
June 2016 |
June 2016 |
November 20, 2013 |
March 29, 2017 |
|
- The Rogosin Institute
New York, New York, United States
|
| 30 |
NCT02808572 |
Recruiting |
New Biomarkers of Bone Mineral Metabolism as Cardiovascular Risk Factors in Chronic Kidney Disease Patients |
|
- Biological: Plasma osteoprotegerin level
- Biological: Plasma fibroblast growth factor 23 level
- Procedure: Vascular calcification score
|
Interventional |
Not Applicable |
- University Hospital, Montpellier
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Occurence of at least one cardiovascular event during the 3 year follow-up according to osteoprotegerin level at inclusion
- Occurence of at least one cardiovascular event during the 3 year follow-up according to fibroblast growth factor 23 level at inclusion
- Occurence of at least one cardiovascular event during the 3 year follow-up according to vascular calcification score at inclusion
- Mortality
|
250 |
All |
18 Years to 95 Years (Adult, Senior) |
NCT02808572 |
UF9125 |
|
March 2013 |
June 2017 |
December 2017 |
June 21, 2016 |
January 18, 2017 |
|
- AIDER
Montpellier, France - CHU Montpellier, Cardiology department
Montpellier, France - CHU Montpellier, Endocrinology department
Montpellier, France - (and 3 more...)
|
| 31 |
NCT01214356 |
Unknown † |
Impact of Vitamin D on Diabetic Kidney Disease in African Americans |
|
|
Interventional |
Not Applicable |
- Medical University of South Carolina
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Progression of Kidney Disease
- Decrease in Estimated Glomerular Filtration Rate (eGFR)
|
102 |
All |
18 Years and older (Adult, Senior) |
NCT01214356 |
1R03DK089120 |
|
February 2010 |
June 2013 |
June 2013 |
October 5, 2010 |
June 14, 2011 |
|
- Medical University of South Carolina
Charleston, South Carolina, United States
|
| 32 |
NCT03036150 |
Recruiting |
A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease |
|
- Drug: Dapagliflozin
- Drug: Placebo
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Time to the first occurrence of any of the components of the composite: ≥50% sustained decline in eGFR or reaching ESRD or CV death or renal death.
- Time to the first occurrence of any of the components of the composite: ≥50% sustained decline in eGFR or reaching ESRD or renal death.
- Time to the first occurrence of either of the components of the composite: CV death or hospitalization for heart failure.
- Time to death from any cause.
|
4000 |
All |
18 Years to 130 Years (Adult, Senior) |
NCT03036150 |
D169AC00001
2016-003896-24 |
Dapa-CKD |
February 2, 2017 |
November 27, 2020 |
November 27, 2020 |
January 30, 2017 |
April 10, 2018 |
|
- Research Site
Birmingham, Alabama, United States - Research Site
Azusa, California, United States - Research Site
Hawaiian Gardens, California, United States - (and 432 more...)
|
| 33 |
NCT03082404 |
Not yet recruiting |
Inspiratory Muscle Training in Chronic Kidney Disease |
|
- Other: Inspiratory muscle training
|
Interventional |
Not Applicable |
- Federal University of Health Science of Porto Alegre
- Irmandade Santa Casa de Misericórdia de Porto Alegre
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Functional capacity
- Muscle strength of inspiratory muscle
- Proximal strength of lower limbs
- (and 2 more...)
|
25 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT03082404 |
HIIMT_CKD |
|
April 3, 2017 |
May 2, 2017 |
June 2, 2017 |
March 17, 2017 |
March 17, 2017 |
|
|
| 34 |
NCT02165878 |
Active, not recruiting |
KoreaN Cohort Study for Outcome in Pediatric Patients With Chronic Kidney Disease |
- Chronic Kidney Disease(CKD)
|
|
Observational |
|
- Seoul National University Hospital
- Jeju National University Hospital
- Pusan National University Hospital
- (and 4 more...)
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- eGFR
- Development of cardiovascular disease
- Metabolic bone disease
- (and 4 more...)
|
458 |
All |
up to 20 Years (Child, Adult) |
NCT02165878 |
2013E3301601
KNOW-PedCKD |
KNOW-PedCKD |
March 2011 |
December 2016 |
December 2021 |
June 18, 2014 |
July 6, 2017 |
|
- Seoul National University Hospital
Seoul, Korea, Republic of
|
| 35 |
NCT02369549 |
Recruiting |
Micro-Particle Curcumin for the Treatment of Chronic Kidney Disease |
|
- Drug: Micro-particle Curcumin
- Drug: Placebo
|
Interventional |
Phase 3 |
- Lawson Health Research Institute
- The Kidney Foundation of Canada
- Canadian Institutes of Health Research (CIHR)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Percent difference between baseline and 24 week (6 month) albuminuria
- Change in Estimated Glomerular Filtration rate (eGFR) from baseline to 24 weeks (6 months)
- Glycemic control as assessed by change in the percentage of glycated hemoglobin
- (and 3 more...)
|
750 |
All |
18 Years and older (Adult, Senior) |
NCT02369549 |
MPAC-CKD |
MPAC-CKD |
September 2015 |
April 2018 |
December 2018 |
February 24, 2015 |
March 22, 2017 |
|
- Kidney Clinical Care Unit
London, Ontario, Canada - University Hospital
London, Ontario, Canada - Victoria Hospital
London, Ontario, Canada
|
| 36 |
NCT01446029 |
Completed |
Telemonitoring to Improve Outcomes of Patients With Chronic Kidney Disease (CKD) |
|
- Device: Video Telemonitoring Device with Clinical Care Modules
|
Interventional |
Phase 3 |
- Minneapolis Veterans Affairs Medical Center
|
U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Prevention
|
- composite clinical outcome (reduce risk of death, hospitalization, emergency room visits, admission to skilled nursing facility)
- reduction of cost
- incidence of end stage kidney disease
- (and 2 more...)
|
601 |
All |
18 Years to 85 Years (Adult, Senior) |
NCT01446029 |
Minn-VAMC-4292-A |
|
March 2012 |
October 2013 |
October 2013 |
October 4, 2011 |
August 4, 2014 |
|
- VA Medical Center
Minneapolis, Minnesota, United States
|
| 37 |
NCT01364779 |
Completed |
Prevalence of Aspirin Resistance in Chronic Kidney Disease Patients |
|
|
Observational |
|
- Northwell Health
- Staten Island University Hospital
|
Other |
- Observational Model: Case Control
- Time Perspective: Cross-Sectional
|
- prevalence of aspirin resistance in chronic kidney disease patients
- risk factors contributing to aspirin resistance in this population.
|
15 |
All |
18 Years and older (Adult, Senior) |
NCT01364779 |
10-025 |
|
April 2010 |
March 2012 |
March 2012 |
June 2, 2011 |
May 15, 2013 |
|
- staten island University Hospital nephrology clinic
Staten Island, New York, United States
|
| 38 |
NCT02830438 |
Recruiting |
Shear Wave Elastography in Native Kidney Disease |
- Acute Kidney Disease
- Chronic Kidney Disease
|
- Device: Shear wave elastography
|
Interventional |
Not Applicable |
- Albert Einstein Healthcare Network
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Shear wave velocity of kidney parenchyma
|
40 |
All |
18 Years and older (Adult, Senior) |
NCT02830438 |
4837
8574 |
|
July 1, 2016 |
December 31, 2017 |
March 31, 2018 |
July 12, 2016 |
August 15, 2017 |
|
- Albert Einstein Healthcare Network
Philadelphia, Pennsylvania, United States
|
| 39 |
NCT02691546 |
Unknown † |
Screening for Chronic Kidney Disease (CKD) Among Older People Across Europe (SCOPE) |
|
- Other: blood sample collection
|
Observational |
|
- Istituto Nazionale di Ricovero e Cura per Anziani
- Ben-Gurion University of the Negev
- ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
- (and 6 more...)
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Rate of estimated Glomerular Filtration Rate (eGFR) decline
- Incidence of End Stage Renal Disease (ESRD)
- Biomarkers of kidney function
- (and 6 more...)
|
2450 |
All |
75 Years and older (Senior) |
NCT02691546 |
INRCA_01_2016
Grant Agreement n. 634869 |
SCOPE |
April 2016 |
April 2018 |
April 2018 |
February 25, 2016 |
February 25, 2016 |
|
- MEDIZINISCHE UNIVERSITAT- Internal Medicine/Nephrology/Geriatric Department
Graz, Austria - FRIEDRICH-ALEXANDER-UNIVERSITAT-Institute for Biomedicine of Aging
Erlangen, Germany - BEN-GURION UNIVERSITY-Geriatrics Department
Beer Sheva, Israel - (and 6 more...)
|
| 40 |
NCT01343641 |
Withdrawn |
Growth Hormone Secretagogue MK-0677's Effect on Lean Body Mass in Chronic Kidney Disease Stage 4/5 Subjects |
- Chronic Kidney Disease
- Kidney Disease
|
- Drug: MK-0677
- Drug: Placebo
|
Interventional |
Phase 2 |
- University of Virginia
- National Institutes of Health (NIH)
- Merck Sharp & Dohme Corp.
|
Other / NIH / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Supportive Care
|
- Lean body weight.
- Cytokine levels
- Hormone levels
- (and 3 more...)
|
0 |
All |
18 Years to 85 Years (Adult, Senior) |
NCT01343641 |
13684
NIH Grant Number-R21DK077372
IND Number-54,041 |
|
March 2009 |
April 2010 |
April 2010 |
April 28, 2011 |
April 27, 2012 |
|
- University of Virginia
Charlottesville, Virginia, United States
|
| 41 |
NCT02160145 |
Completed |
Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease |
- Chronic Kidney Disease
- Autosomal Dominant Polycystic Kidney Disease
|
- Drug: Tolvaptan (OPC-41061)
- Drug: Placebo
|
Interventional |
Phase 3 |
- Otsuka Pharmaceutical Development & Commercialization, Inc.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Treatment difference in the change of eGFR from pre-treatment baseline to post-treatment follow-up, normalized (divided) by each subject's treatment duration
- Treatment difference in annualized slope of eGFR calculated for individual subjects using an appropriate baseline and available, post-randomization, on-treatment assessments
- Plasma tolvaptan and metabolites, including DM-4103 plasma concentrations
- Uosm and urine specific gravity
|
1370 |
All |
18 Years to 65 Years (Adult) |
NCT02160145 |
156-13-210 |
|
May 2014 |
April 14, 2017 |
April 14, 2017 |
June 10, 2014 |
October 17, 2017 |
|
- Birmingham, Alabama, United States
- Huntsville, Alabama, United States
- Mobile, Alabama, United States
- (and 228 more...)
|
| 42 |
NCT01376635 |
Completed |
Depressed Cardiac Autonomic Modulation in Patients With Chronic Kidney Disease Diagnosed by Spectral Analysis |
|
|
Observational |
|
- Core Educational Research and Treatment in Nephrology
|
Other |
- Observational Model: Case-Crossover
|
|
46 |
All |
44 Years to 69 Years (Adult, Senior) |
NCT01376635 |
CoreEdRTNephrology |
HRV |
May 2008 |
|
May 2009 |
June 20, 2011 |
June 20, 2011 |
|
|
| 43 |
NCT00500682 |
Completed
Has Results |
A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease (EPPIC-1) |
|
- Drug: Placebo
- Drug: AST-120
|
Interventional |
Phase 3 |
- Mitsubishi Tanabe Pharma Corporation
- Kureha Corporation
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Composite of Dialysis Initiation, Kidney Transplantation, and Serum Creatinine Doubling. Number of Participants Meeting the Criteria Are Reported.
- Safety and Tolerability
- The Development of a Component of a Quadruple Composite Endpoint (Initiation of Dialysis, Kidney Transplant, Doubling of sCr, or Death), Other Measures of Renal Function
- Vitamins and Folate Levels
|
1020 |
All |
18 Years and older (Adult, Senior) |
NCT00500682 |
KRM-306 |
|
July 2007 |
October 2011 |
October 2011 |
July 13, 2007 |
March 20, 2015 |
March 2, 2015 |
- Phoenix, Arizona, United States
- Little Rock, Arkansas, United States
- Alhambra, California, United States
- (and 102 more...)
|
| 44 |
NCT02031224 |
Completed |
Supplemented Very Low Protein Diet and the Progression of Chronic Kidney Disease |
|
- Behavioral: Conventional low protein diet
- Dietary Supplement: Very low protein diet supplemented with Ketosteril
|
Interventional |
Phase 4 |
- Anemia Working Group Romania
- Dr Carol Davila Teaching Hospital of Nephrology Bucharest
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Primary composite endpoint
- Secondary efficacy parameter
- Secondary outcome measure - nitrogen balance
- (and 9 more...)
|
250 |
All |
18 Years to 85 Years (Adult, Senior) |
NCT02031224 |
AWG13/2007 |
KETOPROG |
March 2008 |
June 2014 |
August 2014 |
January 9, 2014 |
December 22, 2017 |
|
- "Dr Carol Davila" Teaching Hospital of Nephrology
Bucharest, Romania
|
| 45 |
NCT00501046 |
Completed
Has Results |
A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease Including Assessment of Quality of Life (EPPIC-2) |
|
- Drug: Placebo
- Drug: AST-120
|
Interventional |
Phase 3 |
- Mitsubishi Tanabe Pharma Corporation
- Kureha Corporation
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Composite of Dialysis Initiation, Kidney Transplantation, and Serum Creatinine Doubling. Number of Participants Meeting the Criteria Are Reported.
- Safety and Tolerability
- The Development of a Component of a Quadruple Composite Endpoint (Initiation of Dialysis, Kidney Transplant, Doubling of sCr, or Death), Other Measures of Renal Function and (QOL: Exploratory)
- Vitamins and Folate Levels
|
1015 |
All |
18 Years and older (Adult, Senior) |
NCT00501046 |
KRM-307 |
|
July 2007 |
October 2011 |
October 2011 |
July 13, 2007 |
March 20, 2015 |
March 2, 2015 |
- Tuscaloosa, Alabama, United States
- Hot Springs, Arkansas, United States
- Bakersfield, California, United States
- (and 103 more...)
|
| 46 |
NCT00843349 |
Completed
Has Results |
Fibroblast Growth Factor-23 (FGF23) Reduction in Predialysis Chronic Kidney Disease (CKD) |
|
- Drug: Lanthanum Carbonate
- Other: 900 mg Phosphate Diet
- Drug: LC Placebo
- Other: Ad Libitum Diet
|
Interventional |
Not Applicable |
- Myles Wolf
- National Institutes of Health (NIH)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- University of Miami
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Factorial Assignment
- Masking: Single (Participant)
- Primary Purpose: Prevention
|
- Percentage Changes in Fibroblast Growth Factor-23 (FGF-23) Levels
- Percentage Changes in Parathyroid Hormone (PTH) Levels
|
43 |
All |
18 Years and older (Adult, Senior) |
NCT00843349 |
20080536
R01DK076116 |
|
July 2009 |
February 2012 |
March 2012 |
February 13, 2009 |
June 7, 2013 |
June 7, 2013 |
- University of Miami Hospital
Miami, Florida, United States
|
| 47 |
NCT00364884 |
Unknown † |
Keto-/Amino Acid Supplemented Low Protein Diet in Patients With Chronic Kidney Disease |
|
|
Interventional |
Phase 4 |
- National Taiwan University Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Glomerular filtration rate (GFR) and creatinine clearance (Ccr)
- 1. Hemodynamics, 2. Biochemistry status, 3. Bone density analysis, 4. Nutritional status, 5. Urinary status, 6. Compliance check, 7. Incidence of Aes8. Health-related quality of life, 9. Economic benefit
|
50 |
All |
20 Years to 65 Years (Adult) |
NCT00364884 |
941213 |
|
August 2006 |
|
August 2007 |
August 16, 2006 |
August 16, 2006 |
|
|
| 48 |
NCT02250287 |
Completed |
New Quantitive MRI Parameters in Assessing Kidneys of Autosomal Dominant Polycystic Kidney Disease |
- Autosomal Dominant Polycystic Kidney Disease
- Kidney Disease
|
|
Observational |
|
|
Other |
- Observational Model: Case Control
- Time Perspective: Retrospective
|
- Evaluate renal tissue stiffness
- Magnetization transfer ratio
- Diffusion
- Perfusion quantified as blood flow in mL/s.
|
20 |
All |
18 Years to 30 Years (Adult) |
NCT02250287 |
14-000866 |
MRI Pilot |
December 2014 |
March 2016 |
March 2016 |
September 26, 2014 |
June 17, 2016 |
|
- Mayo Clinic
Rochester, Minnesota, United States
|
| 49 |
NCT03303222 |
Not yet recruiting |
Study to Develop a Breath Analyser to Detect Chronic Kidney Disease |
|
|
Observational |
|
- University College, London
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- measurement of breath TMAO
|
100 |
All |
18 Years to 90 Years (Adult, Senior) |
NCT03303222 |
IRAS 228416 |
|
November 10, 2017 |
November 30, 2020 |
November 30, 2020 |
October 5, 2017 |
October 5, 2017 |
|
|
| 50 |
NCT02427594 |
Completed |
Acid-Base Compensation in Chronic Kidney Disease |
|
- Drug: Sodium bicarbonate
- Other: Controlled diet
|
Interventional |
Phase 1 |
- Duke University
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Change in ambulatory blood pressure
- Change in urine net acid excretion
- Change in clinic blood pressure
- Change in plasma nitric oxide metabolites
|
14 |
All |
22 Years and older (Adult, Senior) |
NCT02427594 |
Pro00058905
K23DK095949 |
ABC |
April 2015 |
August 25, 2017 |
August 25, 2017 |
April 28, 2015 |
August 30, 2017 |
|
- Duke University School of Medicine
Durham, North Carolina, United States
|
Create an RSS feed from your search for:
Download the search results for: